Back to top
more

Vanda Pharmaceuticals (VNDA)

(Delayed Data from NSDQ)

$5.32 USD

5.32
448,370

+0.05 (0.95%)

Updated Jul 9, 2024 04:00 PM ET

After-Market: $5.32 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Investors Undervaluing Exelixis (EXEL) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Dynavax Technologies (DVAX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Exelixis (EXEL) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Dynavax Technologies (DVAX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Vanda Pharmaceuticals (VNDA) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of -54.55% and 3.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Bluebird (BLUE) Surges 18%: Is This an Indication of Further Gains?

by Zacks Equity Research

Bluebird (BLUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of -1,000% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Vanda Pharmaceuticals (VNDA) Q1 Earnings Expected to Decline

by Zacks Equity Research

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allogene (ALLO) Misses on Q3 Earnings, Addresses Clinical Hold

by Zacks Equity Research

Allogene (ALLO) misses earnings estimates for the third quarter. However, the stock rises in after-market trading.

Vanda Pharmaceuticals (VNDA) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of -30.00% and -4.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Q3 Release

by Zacks Equity Research

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vanda (VNDA) Upgraded to Buy: Here's Why

by Zacks Equity Research

Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vanda (VNDA) Loses 21.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Vanda (VNDA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Allogene (ALLO) Q2 Earnings Top, Sales Lag, Pipeline Advances

by Zacks Equity Research

Allogene (ALLO) beats earnings estimates but misses the same for revenues in the second quarter.

Sarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised

by Zacks Equity Research

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in Q2. The company also raises revenues guidance for the year. It plans to start a pivotal study on SRP-9001 next month. Stock up.

Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) posts wider-than-expected loss in the second quarter due to rising R&D costs. Sales beat estimates on the encouraging uptake of Qinlock.

Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.

Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.

Vanda (VNDA) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues

by Zacks Equity Research

Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.

Vanda Pharmaceuticals (VNDA) Matches Q2 Earnings Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and -4.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Vanda (VNDA) Moves 5.8% Higher: Will This Strength Last?

by Zacks Equity Research

Vanda (VNDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Benjamin Rains headshot

Find Great Stocks with this New Analyst Coverage Screener

by Benjamin Rains

One way to find potential winners is to search for companies that have landed new analyst coverage recently. And the reasoning is pretty straightforward...

Vanda Pharmaceuticals (VNDA) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Vanda (VNDA) delivered earnings and revenue surprises of 7.14% and 166.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.